Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.22 +1.9%	$8.34	$6.38 ▼ $17.30	$891.93M	1.4	1.24 million shs	1.29 million shs
CBAY CymaBay Therapeutics	$32.48	$32.44	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
KROS Keros Therapeutics	$14.02 -4.2%	$12.94	$9.12 ▼ $72.37	$594.60M	1.32	845,027 shs	550,423 shs
TVTX Travere Therapeutics	$15.38 +2.9%	$17.49	$6.79 ▼ $25.29	$1.37B	0.88	1.58 million shs	1.38 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	+1.88%	+3.83%	+7.08%	+16.56%	-40.86%
CBAY CymaBay Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
KROS Keros Therapeutics	-4.23%	-0.99%	-2.98%	+26.53%	-69.99%
TVTX Travere Therapeutics	+2.88%	-2.04%	-23.41%	-28.13%	+124.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.2848 of 5 stars	3.5	1.0	0.0	0.0	3.5	1.7	0.6
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	2.314 of 5 stars	3.3	1.0	0.0	0.0	2.2	5.0	0.0
TVTX Travere Therapeutics	2.8697 of 5 stars	4.4	2.0	0.0	0.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$19.43	110.72% Upside
CBAY CymaBay Therapeutics	0.00	N/A	N/A	N/A
KROS Keros Therapeutics	2.57	Moderate Buy	$37.00	163.91% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$31.79	106.67% Upside

Current Analyst Ratings Breakdown

Latest TVTX, AVDL, KROS, and CBAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
5/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $25.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$22.00 ➝ $23.00
4/23/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/14/2025	TVTX Travere Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00
4/11/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
4/10/2025	TVTX Travere Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $47.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$194.45M	4.59	N/A	N/A	$0.98 per share	9.41
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
KROS Keros Therapeutics	$214.71M	2.65	N/A	N/A	$11.09 per share	1.26
TVTX Travere Therapeutics	$273.53M	4.99	N/A	N/A	$2.67 per share	5.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$160.28M	-$0.27	N/A	153.67	N/A	-52.53%	-93.34%	-44.77%	8/14/2025 (Estimated)
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	N/A
KROS Keros Therapeutics	-$152.99M	-$0.18	N/A	N/A	N/A	-27,890.94%	-41.74%	-38.42%	8/6/2025 (Estimated)
TVTX Travere Therapeutics	-$111.40M	-$2.81	N/A	N/A	N/A	-137.90%	-1,636.87%	-55.95%	8/7/2025 (Estimated)

Latest TVTX, AVDL, KROS, and CBAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.97	2.60
CBAY CymaBay Therapeutics	N/A	10.96	10.96
KROS Keros Therapeutics	N/A	19.03	19.03
TVTX Travere Therapeutics	24.96	1.71	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
CBAY CymaBay Therapeutics	95.03%
KROS Keros Therapeutics	71.56%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.80%
CBAY CymaBay Therapeutics	7.00%
KROS Keros Therapeutics	20.60%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.74 million	Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
KROS Keros Therapeutics	100	40.62 million	31.23 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	75.12 million	Optionable

TVTX, AVDL, KROS, and CBAY Headlines

Recent News About These Companies

Lost Money on Travere Therapeutics, Inc. (TVTX)? Possible Fraud - Contact Levi & Korsinsky Today

May 29 at 10:25 AM | accessnewswire.com

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29 at 10:00 AM | accessnewswire.com

TVTX Investor Notice: Levi & Korsinsky Investigates Travere Therapeutics, Inc. for Securities Law Violations

May 28 at 1:25 PM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

May 28 at 10:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

May 27 at 11:50 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

May 27 at 10:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

May 26, 2025 | accessnewswire.com

Two Sigma Investments LP Purchases 332,933 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 26, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Raised by Man Group plc

May 26, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Bought by Millennium Management LLC

May 26, 2025 | marketbeat.com

Ameriprise Financial Inc. Purchases 162,649 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 26, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation

May 25, 2025 | accessnewswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Holdings Lifted by Voloridge Investment Management LLC

May 25, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

May 24, 2025 | accessnewswire.com

Two Sigma Advisers LP Grows Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 24, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Nuveen Asset Management LLC

May 24, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

May 23, 2025 | accessnewswire.com

Woodline Partners LP Has $36.83 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 23, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

May 22, 2025 | accessnewswire.com

Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review

May 21, 2025 | investing.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

May 21, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX, AVDL, KROS, and CBAY Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.22 +0.17 (+1.88%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$9.22 +0.00 (+0.05%)

As of 05/29/2025 04:27 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

CymaBay Therapeutics NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Keros Therapeutics NASDAQ:KROS

$14.02 -0.62 (-4.23%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$13.76 -0.26 (-1.89%)

As of 05/29/2025 07:07 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Travere Therapeutics NASDAQ:TVTX

$15.38 +0.43 (+2.88%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$16.22 +0.83 (+5.43%)

As of 05/29/2025 06:06 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time